{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Salivary+Gland+Cancer&page=4",
    "query": {
      "condition": "Recurrent Salivary Gland Cancer",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 128,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Salivary+Gland+Cancer&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Salivary+Gland+Cancer&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T04:09:21.887Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00027534",
      "title": "Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Gallbladder Cancer",
        "Gastric Cancer",
        "Head and Neck Cancer",
        "Liver Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "TRICOM-CEA(6D)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Michael Morse, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2002-01",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2014-09-08",
      "last_synced_at": "2026-10-03T04:09:21.887Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00027534"
    },
    {
      "nct_id": "NCT00458978",
      "title": "Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Hypopharyngeal Squamous Cell Carcinoma",
        "Recurrent Laryngeal Squamous Cell Carcinoma",
        "Recurrent Laryngeal Verrucous Carcinoma",
        "Recurrent Lip and Oral Cavity Squamous Cell Carcinoma",
        "Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary",
        "Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma",
        "Recurrent Oral Cavity Verrucous Carcinoma",
        "Recurrent Oropharyngeal Squamous Cell Carcinoma",
        "Recurrent Salivary Gland Carcinoma",
        "Salivary Gland Squamous Cell Carcinoma",
        "Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary",
        "Stage IV Hypopharyngeal Squamous Cell Carcinoma",
        "Stage IV Laryngeal Squamous Cell Carcinoma",
        "Stage IV Laryngeal Verrucous Carcinoma",
        "Stage IV Lip and Oral Cavity Squamous Cell Carcinoma",
        "Stage IV Major Salivary Gland Carcinoma",
        "Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
        "Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma",
        "Stage IV Oral Cavity Verrucous Carcinoma",
        "Stage IV Oropharyngeal Squamous Cell Carcinoma",
        "Tongue Carcinoma",
        "Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary"
      ],
      "interventions": [
        {
          "name": "Cediranib Maleate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2007-02",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2015-05-05",
      "last_synced_at": "2026-10-03T04:09:21.887Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00458978"
    },
    {
      "nct_id": "NCT00022217",
      "title": "Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cisplatin-e therapeutic implant",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Matrix Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-10-03T04:09:21.887Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Evanston, Illinois + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022217"
    },
    {
      "nct_id": "NCT00081211",
      "title": "Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Salivary Gland Squamous Cell Carcinoma",
        "Stage III Salivary Gland Cancer",
        "Stage III Squamous Cell Carcinoma of the Hypopharynx",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage IV Salivary Gland Cancer",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity"
      ],
      "interventions": [
        {
          "name": "PV701",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2004-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-24",
      "last_synced_at": "2026-10-03T04:09:21.887Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00081211"
    },
    {
      "nct_id": "NCT00898742",
      "title": "Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "DNA and tissue microarray analysis",
          "type": "GENETIC"
        },
        {
          "name": "reverse transcriptase-polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "mass spectrometry",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 58,
      "start_date": "2007-04",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2013-04-02",
      "last_synced_at": "2026-10-03T04:09:21.887Z",
      "location_count": 3,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00898742"
    },
    {
      "nct_id": "NCT00639769",
      "title": "Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2002-02",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2012-09-14",
      "last_synced_at": "2026-10-03T04:09:21.887Z",
      "location_count": 8,
      "location_summary": "Macon, Georgia • Chattanooga, Tennessee • Jackson, Tennessee + 3 more",
      "locations": [
        {
          "city": "Macon",
          "state": "Georgia"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        },
        {
          "city": "Jackson",
          "state": "Tennessee"
        },
        {
          "city": "Johnson City",
          "state": "Tennessee"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00639769"
    },
    {
      "nct_id": "NCT01365169",
      "title": "Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Malignant Head and Neck Neoplasm",
        "Malignant Neoplasm",
        "Metastatic Malignant Neoplasm in the Neck",
        "Metastatic Malignant Neoplasm in the Uterine Cervix",
        "Pancreatic Adenocarcinoma",
        "Pancreatic Neuroendocrine Carcinoma",
        "Recurrent Colorectal Carcinoma",
        "Stage I Colorectal Cancer AJCC v6 and v7",
        "Stage I Hypopharyngeal Carcinoma AJCC v7",
        "Stage I Major Salivary Gland Cancer AJCC v7",
        "Stage I Nasopharyngeal Carcinoma AJCC v7",
        "Stage I Oral Cavity Cancer AJCC v6 and v7",
        "Stage I Oropharyngeal Carcinoma AJCC v6 and v7",
        "Stage II Colorectal Cancer AJCC v7",
        "Stage II Hypopharyngeal Carcinoma AJCC v6 and v7",
        "Stage II Major Salivary Gland Cancer AJCC v7",
        "Stage II Nasopharyngeal Carcinoma AJCC v7",
        "Stage II Oral Cavity Cancer AJCC v6 and v7",
        "Stage II Oropharyngeal Carcinoma AJCC v6 and v7",
        "Stage IIA Colorectal Cancer AJCC v7",
        "Stage IIB Colorectal Cancer AJCC v7",
        "Stage IIC Colorectal Cancer AJCC v7",
        "Stage III Colorectal Cancer AJCC v7",
        "Stage III Hypopharyngeal Carcinoma AJCC v7",
        "Stage III Laryngeal Cancer AJCC v6 and v7",
        "Stage III Major Salivary Gland Cancer AJCC v7",
        "Stage III Nasopharyngeal Carcinoma AJCC v7",
        "Stage III Oral Cavity Cancer AJCC v6 and v7",
        "Stage III Oropharyngeal Carcinoma AJCC v7",
        "Stage IIIA Colorectal Cancer AJCC v7",
        "Stage IIIB Colorectal Cancer AJCC v7",
        "Stage IIIC Colorectal Cancer AJCC v7",
        "Stage IV Colorectal Cancer AJCC v7",
        "Stage IVA Colorectal Cancer AJCC v7",
        "Stage IVA Hypopharyngeal Carcinoma AJCC v7",
        "Stage IVA Laryngeal Cancer AJCC v7",
        "Stage IVA Major Salivary Gland Cancer AJCC v7",
        "Stage IVA Nasopharyngeal Carcinoma AJCC v7",
        "Stage IVA Oral Cavity Cancer AJCC v6 and v7",
        "Stage IVA Oropharyngeal Carcinoma AJCC v7",
        "Stage IVB Colorectal Cancer AJCC v7",
        "Stage IVB Hypopharyngeal Carcinoma AJCC v7",
        "Stage IVB Laryngeal Cancer AJCC v7",
        "Stage IVB Major Salivary Gland Cancer AJCC v7",
        "Stage IVB Nasopharyngeal Carcinoma AJCC v7",
        "Stage IVB Oral Cavity Cancer AJCC v6 and v7",
        "Stage IVB Oropharyngeal Carcinoma AJCC v7",
        "Metastatic or Locally Unresectable Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Exercise Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Health Telemonitoring",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 590,
      "start_date": "2011-05-25",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-10-03T04:09:21.887Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01365169"
    },
    {
      "nct_id": "NCT00003569",
      "title": "Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Head and Neck Cancer",
        "Lung Cancer",
        "Neurotoxicity",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "dimesna",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "1998-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-31",
      "last_synced_at": "2026-10-03T04:09:21.887Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Baltimore, Maryland • Buffalo, New York",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003569"
    },
    {
      "nct_id": "NCT01604772",
      "title": "Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Oral Cavity Adenoid Cystic Carcinoma",
        "Recurrent Salivary Gland Carcinoma",
        "Salivary Gland Adenoid Cystic Carcinoma",
        "Stage IVA Major Salivary Gland Cancer AJCC v7",
        "Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7",
        "Stage IVB Major Salivary Gland Cancer AJCC v7",
        "Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7",
        "Stage IVC Major Salivary Gland Cancer AJCC v7",
        "Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Akt Inhibitor MK2206",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2012-07-23",
      "completion_date": "2014-11-22",
      "has_results": true,
      "last_update_posted_date": "2019-05-01",
      "last_synced_at": "2026-10-03T04:09:21.887Z",
      "location_count": 51,
      "location_summary": "Lewes, Delaware • Newark, Delaware • Jacksonville, Florida + 36 more",
      "locations": [
        {
          "city": "Lewes",
          "state": "Delaware"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01604772"
    },
    {
      "nct_id": "NCT00126607",
      "title": "Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High-grade Salivary Gland Mucoepidermoid Carcinoma",
        "Recurrent Salivary Gland Cancer",
        "Salivary Gland Acinic Cell Tumor",
        "Salivary Gland Adenocarcinoma",
        "Salivary Gland Poorly Differentiated Carcinoma",
        "Stage IVA Salivary Gland Cancer",
        "Stage IVB Salivary Gland Cancer",
        "Stage IVC Salivary Gland Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2005-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-28",
      "last_synced_at": "2026-10-03T04:09:21.887Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00126607"
    }
  ]
}